ARK Genomic Revolution ETF Rating $51.30 +2.01 (+4.08%) Closing price 04:10 PM EasternExtended Trading$51.30 0.00 (-0.01%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Ratings Stock AnalysisChartHoldingsNews and TrendsOwnershipRatingsShort Interest ARK Genomic Revolution ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.ARKG Aggregate RatingModerate Buy 2.54Holdings in ARKG have an aggregate rating of Moderate Buy based on 357 analyst ratings issued in the past year covering 25 companies (94.6% of the portfolio).ARKG Aggregate Price Target$51.30High Prediction$51.30Average Prediction$51.30Low Prediction$51.30Holdings in ARKG have an aggregate price target of $51.30 and a range of $51.30 to $51.30 covering 25 companies (94.6% of the portfolio).ARKG Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy0 Buy rating(s)Moderate Buy15 Moderate Buy rating(s)Hold9 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by ARK Genomic Revolution ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 ARKG Holdings ExportWeight In ETFCompanyShare PriceConsensus RatingConsensus Price TargetPossible UpsideNumber of RatingsMarketRank™Indicator(s)ViewRatings10.23%TXG10x Genomics$80.65+4.4%Hold$58.60 -27.3%181.4967 of 5 starsAnalyst Forecast10.12%TWSTTwist Bioscience$159.78+5.1%Hold$128.17 -19.8%132.0221 of 5 starsAnalyst ForecastInsider TradeHigh Trading Volume8.73%TEMTempus AI$70.93+2.4%Hold$71.05 0.2%222.5274 of 5 stars5.20%CRSPCRISPR Therapeutics$53.39+5.8%Moderate Buy$67.94 27.3%192.9378 of 5 starsTrending NewsAnalyst ForecastInsider Trade5.19%ABSIAbsci$10.16+13.6%Moderate Buy$13.71 35.0%92.6009 of 5 starsGap Up4.71%PSNLPersonalis$16.00-0.4%Hold$14.54 -9.2%111.5814 of 5 starsAnalyst Downgrade4.64%GHGuardant Health$167.47+1.2%Moderate Buy$189.38 13.1%252.3016 of 5 starsAnalyst Forecast4.62%ILMNIllumina$278.17+5.1%Hold$222.19 -20.1%182.2848 of 5 starsAnalyst Forecast4.47%NTRANatera$400.71+2.5%Moderate Buy$353.45 -11.8%231.926 of 5 starsAnalyst Forecast4.41%CDNACareDx$63.67+2.3%Hold$54.00 -15.2%82.3497 of 5 starsAnalyst Upgrade3.17%LLYEli Lilly and Company$1,177.57+0.7%Moderate Buy$1,313.43 11.5%304.8927 of 5 starsTrending NewsAnalyst Forecast3.11%SDGRSchrodinger$27.28+3.4%Moderate Buy$20.80 -23.8%72.2111 of 5 starsPositive News2.94%BEAMBeam Therapeutics$25.70+4.5%Moderate Buy$50.10 94.9%122.2309 of 5 stars2.91%RXRXRecursion Pharmaceuticals$4.36+10.4%Hold$8.06 84.9%51.9618 of 5 starsInsider Trade2.37%VCYTVeracyte$45.23+3.7%Moderate Buy$55.78 23.3%114.0417 of 5 stars2.32%ADPTAdaptive Biotechnologies$26.49+1.5%Moderate Buy$28.94 9.2%82.4827 of 5 starsInsider Trade2.27%CMPSCompass Pathways$12.00+4.6%Moderate Buy$23.36 94.6%172.4837 of 5 stars1.96%BFLYButterfly Network$8.27+2.9%Moderate Buy$8.54 3.3%72.3843 of 5 starsNews CoverageInsider Trade1.76%ARCTArcturus Therapeutics$13.74+6.8%Moderate Buy$22.00 60.1%122.864 of 5 starsAnalyst ForecastGap Up1.68%NRIXNurix Therapeutics$22.35+0.6%Moderate Buy$34.21 53.1%152.2078 of 5 stars1.67%WGSGeneDx$67.33-0.6%Moderate Buy$90.86 34.9%93.6677 of 5 stars1.62%NTLAIntellia Therapeutics$13.07+3.7%Hold$20.72 58.5%233.5495 of 5 starsNews CoverageAnalyst Forecast1.61%IONSIonis Pharmaceuticals$45.28+4.6%Moderate Buy$89.20 97.0%223.2229 of 5 stars1.60%ALMRAlamar Biosciences$25.27-2.5%Moderate Buy$31.80 25.8%73.4277 of 5 starsNews CoverageAnalyst UpgradeLockup ExpirationHigh Trading Volume1.33%PACBPacific Biosciences of California$2.33+1.3%Reduce$1.71 -26.5%61.4093 of 5 starsNews CoverageInsider TradeGap Up This page (BATS:ARKG) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARK Genomic Revolution ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share ARK Genomic Revolution ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
